<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568061</url>
  </required_header>
  <id_info>
    <org_study_id>INOT 44</org_study_id>
    <nct_id>NCT00568061</nct_id>
  </id_info>
  <brief_title>Nitric Oxide in Myocardial Infarction Size</brief_title>
  <acronym>NOMI</acronym>
  <official_title>The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether or not inhaled nitric oxide can decrease
      myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment
      elevation MI (STEMI) who undergo successful percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the trial is to assess whether or not inhaled nitric oxide can decrease
      myocardial infarction (MI) size as a fraction of left ventricular (LV) size at 48-72 hours in
      patients presenting with an ST segment elevation MI who undergo successful percutaneous
      coronary intervention (PCI).

      The primary endpoint for this study will be myocardial infarction size as a fraction of left
      ventricular size at 48-72 hours as measured by contrast-enhanced cardiac MRI.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent of Myocardial Infarction Size to the Fraction of Left Ventricular Size</measure>
    <time_frame>48-72 hours</time_frame>
    <description>The primary endpoint - mean percent of the myocardial infarction size to the fraction of left ventricular size at 48-72 hours was measured by contrast-enhanced cardiac Magnetic Resonance Imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) Size at 48-72 Hours</measure>
    <time_frame>48-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI Size Normalized to Area at Risk</measure>
    <time_frame>48-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Perfusion at Coronary Angiography</measure>
    <time_frame>at completion of primary coronary intervention (PCI)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct Transmurality</measure>
    <time_frame>48-72 hours and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global &amp; Regional Left Ventricular (LV) Function and LV Mass</measure>
    <time_frame>48-72 hours and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global LV Function and Mass</measure>
    <time_frame>between 48-72 hours and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI Size as a Fraction of LV Size</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of ST Segment Elevation Compared With That Observed at Enrollment</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T Levels and CPK-MB Area Under the Curve</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adverse Remodeling Parameters Compared With 48-72 Hrs: Changes in LV End-diastolic Vol, End-systolic Vol, End-diastolic Myocardial Wall Thickness in Infarct, Peri-infarct and Remote Areas, and in Sphericity Index at End-diastole and End-systole</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>ST Elevation MI</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Nitric oxide administered at 80 parts per million (ppm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled nitrogen gas (Placebo) administered at 80 ppm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>Nitric oxide for inhalation</description>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
    <other_name>INOmax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nitrogen gas (placebo) for inhalation</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Nitrogen gas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial infarction and electrocardiographic evidence of ST elevation

          -  No clinical evidence of congestive heart failure

          -  All patients must undergo successful percutaneous coronary intervention for
             thrombolysis in myocardial infarction (TIMI) 0 or 1 coronary flow with resulting TIMI
             2 or 3 flow

          -  Greater than 18 years of age

          -  Signed Institutional Review Board (IRB) approved informed consent

        Exclusion Criteria:

          -  Prior myocardial infarction

          -  Requirement for urgent cardiac surgery

          -  Previous coronary artery bypass graft (CABG) or primary coronary intervention (PCI)

          -  Left bundle branch block

          -  Heart block that is expected to require a temporary pacemaker for greater than 72
             hours

          -  Prior use of thrombolytic therapy for the current event

          -  Unable to tolerate magnetic resonance imaging or unable to tolerate gadolinium
             contrast media, including patients with a calculated creatinine clearance less than 60
             ml/min/1.73m² Body Surface Area (BSA)

          -  Active or recent hemorrhage requiring an invasive procedure for evaluation or
             transfusion within 6 weeks prior to presentation, or hemorrhagic stroke within the 6
             weeks prior

          -  Neutropenia (WBC &lt;2000 (mm)³), Anemia (HCT &lt;30%, Thrombocytopenia (Thrombocytes
             &lt;50,000 (mm)³). It is not necessary to confirm blood counts prior to start of study
             drug in the absence of clinical suspicion.

          -  Known or suspected aortic dissection.

          -  Prior history of pulmonary disease requiring chronic oxygen therapy.

          -  Pregnancy, lactating, and women of childbearing potential.

          -  Medical problem likely to preclude completion of the study.

          -  Use of investigational drugs or device within the 30 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Baldassarre, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac &amp; Vascula Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jack D. Weiler Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeBauer Cardiology</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cardiovascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Utah Imaging</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Hospital</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>TGG 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <results_first_submitted>August 3, 2010</results_first_submitted>
  <results_first_submitted_qc>August 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2010</results_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INOT44</keyword>
  <keyword>NOMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>7 medical centers enrolled subjects. A total of 29 subjects were enrolled in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide administered at 80 ppm</description>
        </group>
        <group group_id="P2">
          <title>Nitrogen Gas</title>
          <description>Nitrogen Gas (Placebo) administered at 80 ppm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inclusion / exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide administered at 80ppm</description>
        </group>
        <group group_id="B2">
          <title>Nitrogen Gas</title>
          <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="11.71"/>
                    <measurement group_id="B2" value="63.8" spread="12.41"/>
                    <measurement group_id="B3" value="63.1" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent of Myocardial Infarction Size to the Fraction of Left Ventricular Size</title>
        <description>The primary endpoint - mean percent of the myocardial infarction size to the fraction of left ventricular size at 48-72 hours was measured by contrast-enhanced cardiac Magnetic Resonance Imaging (MRI).</description>
        <time_frame>48-72 hours</time_frame>
        <population>Analysis was per intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of Myocardial Infarction Size to the Fraction of Left Ventricular Size</title>
          <description>The primary endpoint - mean percent of the myocardial infarction size to the fraction of left ventricular size at 48-72 hours was measured by contrast-enhanced cardiac Magnetic Resonance Imaging (MRI).</description>
          <population>Analysis was per intent to treat population</population>
          <units>percent of myocardial infarction size</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="8.99"/>
                    <measurement group_id="O2" value="12.5" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) Size at 48-72 Hours</title>
        <time_frame>48-72 hours</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and Clinical Study Report (CSR) are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide</title>
            <description>nitric oxide for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) Size at 48-72 Hours</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and Clinical Study Report (CSR) are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MI Size Normalized to Area at Risk</title>
        <time_frame>48-72 hours</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>MI Size Normalized to Area at Risk</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Perfusion at Coronary Angiography</title>
        <time_frame>at completion of primary coronary intervention (PCI)</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Perfusion at Coronary Angiography</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infarct Transmurality</title>
        <time_frame>48-72 hours and 4 months</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Infarct Transmurality</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global &amp; Regional Left Ventricular (LV) Function and LV Mass</title>
        <time_frame>48-72 hours and 4 months</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Global &amp; Regional Left Ventricular (LV) Function and LV Mass</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global LV Function and Mass</title>
        <time_frame>between 48-72 hours and 4 months</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global LV Function and Mass</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MI Size as a Fraction of LV Size</title>
        <time_frame>4 months</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>MI Size as a Fraction of LV Size</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of ST Segment Elevation Compared With That Observed at Enrollment</title>
        <time_frame>4 hours</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of ST Segment Elevation Compared With That Observed at Enrollment</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Troponin T Levels and CPK-MB Area Under the Curve</title>
        <time_frame>48 hours</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Troponin T Levels and CPK-MB Area Under the Curve</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Adverse Remodeling Parameters Compared With 48-72 Hrs: Changes in LV End-diastolic Vol, End-systolic Vol, End-diastolic Myocardial Wall Thickness in Infarct, Peri-infarct and Remote Areas, and in Sphericity Index at End-diastole and End-systole</title>
        <time_frame>4 months</time_frame>
        <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Adverse Remodeling Parameters Compared With 48-72 Hrs: Changes in LV End-diastolic Vol, End-systolic Vol, End-diastolic Myocardial Wall Thickness in Infarct, Peri-infarct and Remote Areas, and in Sphericity Index at End-diastole and End-systole</title>
          <population>All efforts have been exhausted to locate data for this historical trial - the validated summary tables and CSR are no longer accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide administered at 80ppm</description>
        </group>
        <group group_id="E2">
          <title>Nitrogen Gas</title>
          <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retropertioneal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The validated summary tables and CSR are not available for this legacy registration that was transferred to us eight years after it was terminated for low enrollment, so posting of results for secondary outcome measures is not possible.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt Pharmaceuticals</organization>
      <phone>800-556-3314</phone>
      <email>clinicaltrials@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

